For Adaptimmune Therapeutics plc (ADAP), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.4. Splitting up the data highlights that, out of 8 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 4 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.23 in the current quarter.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) trade information

In the face of being in the red today for losing -2.92%, in the last five days ADAP remained trading in the green while hitting it’s week-highest on Friday, Jun 19 when the stock touched $10.23- price level, adding 8.99% to its value on the day. Adaptimmune Therapeutics plc’s shares saw a change of 675.83% in year-to-date performance and have moved -6.9% in past 5-day. Adaptimmune Therapeutics plc (NASDAQ:ADAP) showed a performance of 61.35% in past 30-days. Number of shares sold short was 558.77 Million shares which calculate 186.26 days to cover the short interests.

Adaptimmune Therapeutics plc (ADAP) estimates and forecasts

Statistics highlight that Adaptimmune Therapeutics plc is scoring comparatively lower than the scores of other players of the relevant industry. The company added +621.05% of value to its shares in past 6 months, showing an annual growth rate of -26.52% while that of industry is 9.5. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 41% in the current quarter and calculating 30.6% increase in the next quarter. This year revenue growth is estimated to rise 220% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $930Million for the same. And 6 analysts are in estimates of company making revenue of $930Million in the next quarter that will end in September 01, 2020. Company posted $157Million and $237Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 492.4% while estimating it to be 292.4% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -46.4% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -33.2% while estimates for its earnings growth in next 5 years are of 1%

Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s Major holders

Insiders are in possession of 0.2% of company’s total shares while institution are holding 50.74% percent of that, with stock having share float percentage of 50.84%. Investors also watch the number of corporate investors in a company very closely, which is 53 institutions for Adaptimmune Therapeutics plc that are currently holding shares of the company. Matrix Capital Management is the top institutional holder at ADAP for having 34.43 Million shares of worth $93.65 Million. And as of March 30, 2020, it was holding 4.41% of the company’s outstanding shares.

The second largest institutional holder is NEA Management Company, LLC, which was holding about 17.08 Million shares on March 30, 2020. The number of shares represents firm’s hold over 2.19% of outstanding shares, having a total worth of $46.46 Million.

On the other hand, Smallcap World Fund and Old Westbury Small & Mid Cap Strategies Fund are the top two Mutual Funds which own company’s shares. As of December 30, 2019, the former fund manager was holding 7419700 shares of worth $8.9 Million or 0.95% of the total outstanding shares. The later fund manager was in possession of 673.86 Thousand shares on January 30, 2020, making its stake of worth around $2.63 Million in the company or a holder of 0.09% of company’s stock.